• Press Release

Pathology Department Gets New Chair

Carlos Cordon-Cardo, MD, PhD, was appointed Chair of the Department of Pathology.

  • New York, NY
  • (June 08, 2011)

Carlos Cordon-Cardo, MD, PhD, a distinguished physician-scientist who is internationally recognized for his groundbreaking research in experimental pathology and molecular oncology, has been appointed Chair of the Department of Pathology at The Mount Sinai Medical Center. 

Dr. Cordon-Cardo is a leader in the mechanisms of tumor suppression. His research has focused on the analyses of multidrug resistance and alteration of tumor suppression genes in human cancer. He developed and implemented an oncologic molecular pathology discipline, and helped create the "systems pathology" platform. This approach uses systems biology to form mathematical models of the interaction and behavior of cancer cells with the goal of determining tumor pathogenesis and clinical outcome. 

"Mount Sinai is at the forefront of discovery and innovation in cancer research," says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. "Dr. Cordon-Cardo will draw upon his experience as an outstanding investigator, administrator, and educator to bring the Department of Pathology to the top echelon of American Pathology. His vision for enhancing both clinical and research programs will strengthen and grow this mission-critical department." 

Dr. Cordon-Cardo has outlined a broad vision that aims to recruit senior and junior faculty, identify and develop subspecialty areas, such as molecular and systems pathology programs, and expand biorepositories and databases to further translational research. "The institution’s ability to integrate advances in molecular medicine, including cancer biology and genetics, as well as targeted and cell-based therapies into clinical care, very much depends on the reorientation and expansion of the Department of Pathology," he says. 

Dr. Cordon-Cardo’s contributions to cancer research have had important implications for tumor suppression, particularly in bladder and prostate cancers, and soft tissue sarcomas. Currently, his research is aimed at understanding the cooperative effects of mutations of cell-cycle regulation, and genes that prevent cell death cancer. Additionally, he is developing and characterizing animal models for loss of function of specific pathways by targeted gene disruption using bladder cancer and sarcomas. Recent studies from his laboratory have linked adult stem cells and cancer, revealing that certain tumors originate from distinct differentiation stages in stem-cell fate and development. 

A frequently cited author, Dr. Cordon-Cardo has received National Cancer Institute funding for his research. He has developed numerous patents, is a dedicated mentor, and he holds prominent posts in several national and international professional organizations. 

Prior to joining Mount Sinai, Dr. Cordon-Cardo served as Vice-Chair of Pathology, Professor of Pathology, and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons. He also created the Division of Molecular Pathology at Memorial Sloan-Kettering Cancer Center and served as its first director.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.

Related Articles
Nanotechnology
sampson
Lab tests